Purpose The research objectives of the Right to Care Clinical HIV Cohort analyses are to: (1) monitor treatment outcomes (including death, loss to follow-up, viral suppression and CD4 count gain among others) for patients on antiretroviral therapy (ART); (2) evaluate the impact of changes in the national treatment guidelines around when to initiate ART on HIV treatment outcomes; (3) evaluate the impact of changes in the national treatment guidelines around what ART regimens to initiate on drug switches; (4) evaluate the cost and cost-effectiveness of HIV treatment delivery models; (5) evaluate the need for and outcomes on second-line and third-line ART; (6) evaluate the impact of comorbidity with non-communicable diseases on HIV treatment outcomes and (7) The cohort currently has data on over 115 000 patients initiated on HIV treatment and patients are followed up every 3-6 months for clinical and laboratory monitoring. Findings to date Cohort data includes information on demographics, clinical visit, laboratory data, medication history and clinical diagnoses. The data have been used to identify rates and predictors of first-line failure, to identify predictors of mortality for patients on second-line (eg, low CD4 counts) and to show that adolescents and young adults are at increased risk of unsuppressed viral loads compared with adults. Future plans Future analyses will inform national models of HIV care and treatment to improve HIV care policy in South Africa.
IntroductIon
As we enter the second decade of large-scale access to antiretroviral therapy (ART) in sub-Saharan Africa, there is little question about the role that clinical cohorts have played in both evaluating and shaping HIV policy within the continent. [1] [2] [3] South Africa, with the largest HIV treatment programme in the world and over 3 million people on ART, has been a leader in this area. The numerous clinical cohorts that were established since 2004 [4] [5] [6] [7] have been used to evaluate the changes in national treatment policy. One of these cohorts, the Themba Lethu Clinical Cohort 8 was established at the Helen Joseph Hospital in Johannesburg and has led to numerous insights into the effectiveness of the treatment roll-out and also participates in larger country-wide and region-wide evaluations through the International Epidemiologic Database to Evaluate AIDS (IeDEA) network. 7 9 However, the Themba Lethu cohort is based at a large urban tertiary hospital and as the responsibility for HIV care and treatment shifts from hospital based programs to primary ► The biggest strength of the Right to Care Clinical cohort is its size. With over 115 000 patients ever initiated onto HIV treatment, precise evaluations can be conducted. This is particularly important when describing outcomes among subsets of the cohort that could not be conducted with much precision using individual clinic data. ► Second, while the clinics use a similar treatment protocol and data collection strategies, they show geographic variation. While other cohort collaborations do have such geographic variation, few were designed to encompass clinics which shared a common software and approach to data collection. Further because we link the data to the National Health Laboratory Service and the National Population Registry, we have high-quality, nearly complete data on mortality (for citizens who provide an ID), viral load and CD4 counts as well as laboratory tests for antiretroviral monitoring such as haemoglobin and creatinine. ► The main weakness of the data is the lack of standardised follow-ups. Because the cohort follows changing national guidelines and because specific research-based efforts to get patients to adhere to treatment visit schedules are not performed, we do not always have standard monitoring points for all patients within the cohort. This can make interpretation of results difficult and requires careful consideration of the meaning of missing data. . Thus, each clinic within the network follows a common data entry protocol and uses a standard database for data capture. [15] [16] [17] [18] [19] [20] [21] opportunistic infections [22] [23] [24] and adverse drug events, 10 25 because the cohort is large and the clinics are diverse in location and staff mix but provide care according to a standard protocol, [26] [27] [28] [29] they also create an excellent environment for evaluating large policy changes like the recent move to treatment for all, South Africa's national adherence strategy and South Africa's national decanting strategy. In addition, such large collaborations are needed both to triangulate the results of other large collaborations such as IeDEA 30 and to create cohorts large enough to evaluate future needs. These include the coming wave of patients failing first-line 31 and second-line treatment 12 32-34 and needing access to expensive thirdline regimens or the needs of key populations such as pregnant women 35 and adolescents in HIV care. Since the large-scale roll-out of ART in South Africa in 2004, the recommended drug regimens for both first-line and second-line ART have evolved (first-line regimens shown in figure 2 ). Within the cohort, 39 244 patients are currently on first-line ART. Since 2004, threedrug first-line therapy has been non-nucleoside reverse transcriptase inhibitor (NNRTI) based, with efavirenz preferred, but nevirapine is also available. In addition to lamivudine, stavudine was the favoured nucleoside reverse transcriptase inhibitor in the early years but in 2010 tenofovir was recommended.
South Africa monitors the effectiveness of HIV treatment using viral loads. For patients who have documented first-line failure (defined as two consecutive viral loads≥1000 copies/mL 3 at least 2 weeks apart), switching to second-line protease inhibitor-based therapy (typically lopinavir-ritonavir) is recommended. A total of 5909 patients are currently on second-line ART, making it one of the largest second-line cohorts in Africa. More recently, access to third-line ART has become available for patients failing second-line. Access is managed by application to a national third-line committee that will order resistance testing and prescribe an appropriate thirdline regimen based on the results. Third-line consists of any of darunavir, raltegravir and etravirine. Currently, 129 patients have been initiated on third-line within the cohort.
Follow-up measures
Protocols for follow-up of patients on ART within the clinics follow national HIV treatment guidelines that have changed over the years. While initially patients were required to be seen each month to collect antiretrovirals (ARVs), as the programme has matured, patients who have been demonstrated to be adherent and stable on treatment can be prescribed 2 or 3 months of ART at a time, allowing for fewer visits, a reduced burden on the patient and lower clinic volume on a daily basis. A total of 116 490 patients who had ART within the cohort have contributed a total of 3 42 931 person-years on ART. The median (IQR) duration of follow-up per person has been 2.17 (0.81-4.41) person-years with a range of 0.04 to 12.5 person-years. This equates to 1 597 690 total medical and 2 262 626 pharmacy visits at a rate of 6.6 per year. Laboratory investigations for all the clinics in the cohort are conducted by the National Health Laboratory Service (NHLS). While NHLS sends back individual reports to the clinics with the results of each investigation, within the cohort, data from the NHLS are downloaded directly and are integrated into the individual patient database on a daily basis, allowing complete and accurate data on lab investigations.
Open Access Since the beginning of the programme, CD4 counts have been used to determine ART eligibility, with the first viral load monitoring being conducted at between 4 and 6 months on treatment. The interval for monitoring has changed from every 6 months after the initial viral load, to a 6-month and 12-month viral load and then a repeat viral load every year as of 2013. Cohort patients had a median (IQR) of 2.1 (0.48-4.6) viral loads per year and a median (IQR) of 3 (2-7) viral loads per person. Figure 3 shows the increase in numbers on ART and the proportion of patients virally suppressed with changes in the national guidelines.
Because of the richness and size of the cohort, the data have been used to conduct important evaluations of the impact of second-line treatment, 13 36 of transfer between clinics, 15 of the impact of changes in CD4 thresholds on clinic crowding, 37 as well as of the impacts of the shift to tenofovir in replacement of stavudine 11 38 in the national programme. In addition, when warranted, analyses of subsets of the data are used to conduct urgent evaluations such as the impact of pregnancy on retention, 35 outcomes within patients on second-line ART 33 and outcomes for adolescents on ART. 39 The data have also been successfully used by doctoral students for dissertation work. 37 
data collection
As noted, all clinics within the cohort have employed a common patient data collection system since 2004, the TherapyEdge-HIV (TM) patient management system. The system is a longitudinal database designed to capture essential information from all HIV-related clinic visits. 40 Data are captured on patients both prior to ART initiation and after. While the CD4 threshold for ART initiation has changed over time, the protocol for patients prior to initiation has been 6-monthly monitoring of CD4 count until eligibility is established.
For each patient interaction at a cohort clinic, the date of the encounter is recorded allowing for longitudinal follow-up. At the first visit, demographics data are collected including key identifiers and information on age, sex, race, education, alcohol use and smoking. When possible national identifiers are collected to allow linkage with national registries and phone numbers are collected to allow for patient tracing should patients become lost to follow-up. At each follow-up visit, data on clinical conditions that are identified (such as side effects, TB and so on) are captured. At each visit, information is also
Open Access recorded on any medication dispensed including ARVs and other medications.
Overall retention in HIV care in sub-Saharan Africa is less than ideal. [41] [42] [43] Because one of the main uses of these data has been to describe the cascade of HIV care, 44 45 no attempts are made to influence retention for research purposes. Instead, all measures are taken to reduce attrition as part of usual clinical care. All the clinics within the cohort attempt to trace patients who are lost to follow-up, though with differing intensities. Each clinic uses its own definition of loss for triggering tracing activities, though a common definition of 3 months late for an appointment is used for research purposes and standardising loss rates across clinics. At all clinics, tracing is initially done through calling the phone number collected at enrolment. Some of the clinics also employ tracers or use community outreach workers to attempt to trace patients who do not return to care.
Mortality is ascertained in multiple ways within the cohort. All sites use passive follow-up to identify patients who have died and record the information when it is reported back by a family member or friend. In addition, data on all patients who have provided a national identification number and who are lost to follow-up are cross-referenced with South Africa's National Population Register 15 (NPR) to determine final outcomes. The proportion of patients who are either in possession of, or report their national ID number varies from clinic to clinic, ranging from 35% to 74%. Prior to the initial linkage between Themba Lethu Clinic and the NPR, 17% of patients within the clinic were considered lost to follow-up and 4% were known to have died. After linkage, the proportion who were considered to be lost dropped to 10% and the proportion who were recorded to have died increased to 11%. 15 Another way patients leave the cohort is through transfer to another treatment facility. When the patient formally requests this it is noted in the database as a patient outcome. The rate of transfer within the cohort is 12% and varies from 11% to 50%, though those at the higher end see this as intentional transfers of patients who are 'down-referred' to smaller clinics once stable. 46 47 However, as is common within HIV treatment programmes within the region, transfers are often 'silent transfers' where patients transfer without informing their current clinic. Patients who transfer to a new clinic outside our network without informing us will appear as lost to follow-up. We have shown that this can bias estimates of retention in care, 48 and therefore the clinics within the cohort request patients notify the clinic if they wish to receive care elsewhere so that care can be coordinated.
FIndIngs to dAte
The Right to Care Clinical Cohort is used to monitor the continued roll-out of ART in South Africa and to evaluate the impact of changes in the national treatment programme as they are made. Current areas of research include: (1) monitoring treatment outcomes (including death, loss to follow-up, viral suppression, CD4 count gain, etc) for patients on ART; (2) evaluating the impact of changes in the national treatment guidelines around when to initiate ART on HIV treatment outcomes; (3) evaluating the impact of changes in the national treatment guidelines around what ART regimens to initiate on drug switches; (4) evaluating the cost and cost-effectiveness of HIV treatment delivery models; (5) evaluating the need for and outcomes on secondline and third-line ART; (6) evaluating the impact of comorbidity with non-communicable diseases on HIV treatment outcomes and (7) evaluating the impact of the switch to initiating all patients onto ART regardless of CD4 count.
To date, we have used the Right to Care cohort to evaluate various aspects of the national HIV treatment programme. Three examples of this work include: ► Treatment outcomes. While numerous models have found important predictors of failing first-line therapy, few have had the size to be able to develop a precise predictive model of treatment failure. 49 Using data on 71 154 individuals, we showed that age, sex, interactions between age and sex, first-line NNRTI, CD4 count, mean corpuscular volume, haemoglobin level, history of TB and missed visits during the first 6 months on ART were predictive of failure. After stratifying into risk groups, failure in the highest risk group was 24.4% over 5 years on ART but only 9.4% among the lowest risk group, allowing stratification of risk for clinics.
49
► Second-line ART outcomes. The need for second-line treatment has been growing as treatment scale up has continued, but there is little robust data on outcomes among patients who have already failed a first-line regimen. 34 With data on 1435 patients on second-line ART between 2004 and 2013, we found that a low CD4 count (<50 cells/mm 3 ) at the time of switch was strongly predictive of mortality (adjusted HR (aHR) vs ≥200 cells/mm 3 : 3.76; 95% CI: 1.87 to 7.57) as was a high viral load (≥50 000 copies/mL vs 1000-4999 copies/mL aHR: 2.01; 95% CI: 1.07 to 3.77). 33 The results suggest that earlier switch would likely benefit patients failing first-line before disease progresses to severe immunosuppression. Perhaps the biggest strength of the Right to Care Clinical cohort is its size. With over 1 15 000 patients ever initiated onto HIV treatment, precise evaluations can be conducted. This is particularly important when describing outcomes among subsets of the cohort that could not be conducted with much precision using individual clinic data. For example, by pooling data across 10 clinics, we are able to conduct precise analyses on a large cohort of patients initiating second-line therapy.
Second, while the clinics use a similar treatment protocol and data collections strategies, they show geographic variation. While other cohort collaborations do have such geographic variation, few were designed to encompass clinics which shared a common software and approach to data collection. Further because we link the data to the NHLS and the National Population Registration, we have high-quality, nearly complete data on mortality (for citizens who provide an ID), viral load and CD4 counts as well as ARV monitoring labs such as haemoglobin and creatinine.
Perhaps the main weakness of the data is the lack of standardised follow-ups. Because the cohort follows changing national guidelines and because specific research-based efforts to get patients to adhere to treatment visit schedules are not performed, we do not always have standard monitoring points for all patients within the cohort. This can make interpretation of results difficult and requires careful consideration of the meaning of missing data. It also calls for the use of missing data methods 50 and formal quantitative bias analysis [51] [52] [53] [54] to explore the impact of any systematic errors. In addition, because the cohort is not designed as a research cohort, biological samples are not collected at routine intervals (beyond what is required for clinical care) and these samples are not stored. Therefore, we cannot use the cohort to study topics such as molecular epidemiology or biomarker research. Because the cohort is meant to reflect what is happening in actual clinic care, such samples will continue to not be stored going forward.
collAborAtIons Investigators wishing to work with the data should contact the team at the Health Economics and Epidemiology Research Office ( information@ heroza. org) and send a concept sheet for the analyses they are interested in performing and the variables that would be required. Anyone wishing to work with the data from the Right to Care Cohort must seek Institutional Review Board approval from both their own institutions and from the Human Research Ethics Committee (Medical) of the University of the Witwatersrand. After receiving such approvals, those wishing to work with the data must sign a data-use agreement. Those wishing to find out more about the Right to Care cohort can visit the website of the Health Economics and Epidemiology Research Office in Johannesburg, South Africa, at http://www. heroza. org/.
correction notice This paper has been amended since it was published Online First. Owing to a scripting error, some of the publisher names in the references were replaced with 'BMJ Publishing Group'. This only affected the full text version, not the PDF. We have since corrected these errors and the correct publishers have been inserted into the references. Mhairi Maskew was correctly listed as the second author but then listed again at the end of the author list. This has been corrected so he only appears once in the author list.
Acknowledgements The authors wish to thank Babatyi Malope-Kgokong for her efforts and input in developing the database. We also thank Ms. Imogen Jaffray and the TherapyEdge-HIV team as well as the data capturers who helped collect the data. Most importantly, we thank the patients who contributed to this cohort.
contributors MPF and MM conceptualised the study. MPF and MM wrote the first draft. GM conducted the data analysis. MPF, MM, ATB, DE, DO, GM, PM, JB, OE, DM, SM, LL and IS contributed to interpreting the data and to the writing and revising of the manuscript. Funding This study is made possible by the generous support of the American people through Cooperative Agreement AID 674-A-12-00029 from the US Agency for International Development (USAID).
disclaimer The contents are the responsibility of the authors and do not necessarily reflect the views of USAID or the US Government. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http:// creativecommons. org/ licenses/ by-nc/ 4. 0/
